Evidence map›Paper›PMID 38361931›Full record

ReviewFrontiers in immunology2024

Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target.

Conner Hartupee, Bolni Marius Nagalo, Chiswili Y Chabu, Mulu Z Tesfay, Joycelynn Coleman-Barnett, John T West, Omeed Moaven

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
23.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 82 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Pan-cancer characterization ofTranslational cancer research · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Progress and challenges in the development of advanced pancreatic cancer organoids.Journal of experimental & clinical cancer research : CR · 2026
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Modulating tumor mechanics and vascular barriers to enhance chemotherapy efficacy in pancreatic tumors and melanoma.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Conner HartupeeDivision of Surgical Oncology, Department of Surgery, Louisiana State University (LSU) Health, New Orleans, LA, United States.
Bolni Marius NagaloDepartment of Pathology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, United States.
Chiswili Y ChabuDivision of Biological Sciences, University of Missouri, Columbia, MO, United States.
Mulu Z TesfayDepartment of Pathology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, United States.
Joycelynn Coleman-BarnettDivision of Surgical Oncology, Department of Surgery, Louisiana State University (LSU) Health, New Orleans, LA, United States.
John T WestDepartment of Interdisciplinary Oncology, Louisiana Cancer Research Center, Louisiana State University (LSU) Health, New Orleans, LA, United States.
Omeed MoavenDivision of Surgical Oncology, Department of Surgery, Louisiana State University (LSU) Health, New Orleans, LA, United States.
Louisiana Cancer Research Center · USLouisiana State University Health Sciences Center New Orleans · USUniversity Medical Center New Orleans · USUniversity of Arkansas for Medical Sciences · USWashington University in St. Louis · USWinthrop Rockefeller Foundation · US

Funding

Translational Genomics Core (TGC)P20GM121288 · NIGMS · LSU HEALTH SCIENCES CENTER · PI Arunava Roy · 2017 to 2026
$22.4M
NIGMS NIH HHS P20 GM121288
6 · The paper itself

Abstract

Pancreatic Ductal Adenocarcinoma (PDAC) is projected to become the 2nd leading cause of cancer-related deaths in the United States. Limitations in early detection and treatment barriers contribute to the lack of substantial success in the treatment of this challenging-to-treat malignancy. Desmoplasia is the hallmark of PDAC microenvironment that creates a physical and immunologic barrier. Stromal support cells and immunomodulatory cells face aberrant signaling by pancreatic cancer cells that shifts the complex balance of proper repair mechanisms into a state of dysregulation. The product of this dysregulation is the desmoplastic environment that encases the malignant cells leading to a dense, hypoxic environment that promotes further tumorigenesis, provides innate systemic resistance, and suppresses anti-tumor immune invasion. This desmoplastic environment combined with the immunoregulatory events that allow it to persist serve as the primary focus of this review. The physical barrier and immune counterbalance in the tumor microenvironment (TME) make PDAC an immunologically cold tumor. To convert PDAC into an immunologically hot tumor, tumor microenvironment could be considered alongside the tumor cells. We discuss the complex network of microenvironment molecular and cellular composition and explore how they can be targeted to overcome immuno-therapeutic challenges.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsHumansImmunomodulationSignal TransductionTumor Microenvironmentcancer immunologyimmune therapeuticspancreatic adenocarcinomaPDAC TMEtumor immune microenvironmenttumor microenvironment

Identifiers

PMID38361931
PMCPMC10867137
OpenAlexW4391445805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.